News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13R?2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology

Al's Comment:

 CAR T Cell therapy has been one of the most promising therapies in other types of cancer (although a large CAR T Cell trial for leukemia was recently placed on hold due to a few treatment related deaths). Here the researchers bring it to GBMs, and shows early signs of it helping.  More work needs to be done to optimize the delivery and the targets (Other researchers are using CAR T Cells targeting EGFRvIII see clinicaltrials.gov/ct2/show/NCT02664363) .  This study targeted IL13Rα2, which is another good target, but neither target is presnet in 100% of tumors. Perhaps combining them would reach the majority of patients.


Posted on: 11/25/2016

Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology

www.econotimes.com/Clinical-and-Pre-Clinical-Data-on-Mustang-Bios-MB-101-IL13R%CE%B12-specific-CAR-T-cells-for-the-Treatment-of-Glioblastoma-GBM-Presented-at-the-21st-Annual-Meeting-and-Education-Day-of-the-Society-for-Neuro-Oncology-412496

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740